[ATOS] Atossa Genetics Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.38 Change: -0.02 (-1.43%)
Ext. hours: Change: 0 (0%)

chart ATOS

Refresh chart

Strongest Trends Summary For ATOS

ATOS is in the long-term down -100% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Fundamental Ratios
Shares Outstanding EPS-2.28 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 18630% Sales Growth - Q/Q283.03% P/E-0.22
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-112.88% ROE-151.51% ROI
Current Ratio3.26 Quick Ratio3.23 Long Term Debt/Equity Debt Ratio0.34
Gross Margin Operating Margin-653.31% Net Profit Margin-656.04% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.29 M Cash From Investing Activities-70 K Cash From Operating Activities-3 M Gross Profit670 K
Net Profit-3.34 M Operating Profit-3.28 M Total Assets13.8 M Total Current Assets11.37 M
Total Current Liabilities3.49 M Total Debt110 K Total Liabilities3.52 M Total Revenue1.87 M
Technical Data
High 52 week7.07 Low 52 week0.92 Last close2.54 Last change0.79%
RSI29.7 Average true range0.16 Beta0.87 Volume177.7 K
Simple moving average 20 days-11.13% Simple moving average 50 days-18.15% Simple moving average 200 days31.2%
Performance Data
Performance Week-1.93% Performance Month-3.05% Performance Quart68.21% Performance Half96.9%
Performance Year-49.34% Performance Year-to-date149.02% Volatility daily6.28% Volatility weekly14.04%
Volatility monthly28.78% Volatility yearly99.7% Relative Volume171.06% Average Volume3.09 M
New High New Low


2020-05-29 08:00:10 | SARS-CoV-2 was spreading in the United States in late December 2019 and may have killed over 440 patients in California and 980 nationwide by mid-January 2020

2020-05-28 09:30:10 | Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study

2020-05-20 09:30:10 | Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

2020-05-13 09:30:10 | Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs

2020-05-07 09:30:10 | Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment

2020-05-07 08:00:10 | Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs

2020-04-27 08:00:10 | Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study

2020-04-22 15:40:26 | Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’

2020-04-20 08:00:10 | Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study

2020-04-17 10:51:41 | COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted

2020-04-16 08:00:10 | Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program

2020-04-02 08:00:10 | Atossa Therapeutics Announces Clinical Progress

2020-03-30 08:00:10 | New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients

2020-03-26 08:00:10 | Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update

2020-03-13 08:30:10 | Atossa Therapeutics Announces Upcoming Meeting with FDA

2020-03-02 08:30:10 | Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density

2020-02-05 08:00:10 | Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

2020-02-04 17:10:00 | Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day _Transforming Breast Cancer Treatment_

2020-01-22 08:30:10 | Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

2020-01-06 08:00:10 | Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.

2019-12-19 08:30:10 | Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women

2019-12-16 11:09:22 | Is Atossa Genetics NASDAQ:ATOS In A Good Position To Deliver On Growth Plans?

2019-12-05 08:30:10 | Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

2019-11-13 08:00:00 | Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

2019-10-23 08:30:05 | Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

2019-10-16 08:30:00 | Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

2019-10-15 08:30:00 | Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

2019-09-30 08:30:00 | Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

2019-09-06 08:30:00 | Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

2019-09-03 08:00:00 | Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

2019-08-13 13:26:06 | Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update

2019-07-30 08:30:00 | Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk

2019-07-17 08:30:00 | Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests

2019-07-11 08:30:00 | Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated

2019-06-28 11:38:23 | A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019

2019-06-27 08:00:00 | Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density

2019-06-19 15:56:16 | Some Atossa Genetics NASDAQ:ATOS Shareholders Have Copped A 99% Share Price Wipe Out

2019-05-30 08:00:00 | Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019

2019-05-13 17:21:57 | Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update

2019-04-30 06:10:00 | _The Digital Economy & World Markets_

2019-04-25 12:00:00 | Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit

2019-04-22 08:45:00 | Reducing This Amino Acid May Aid In Fight Against Breast Cancer

2019-04-22 08:30:00 | Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019

2019-03-28 16:30:00 | Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

2019-03-27 10:15:00 | _Bull Market Hopping?_

2019-03-26 08:30:00 | Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

2019-03-18 08:30:00 | Atossa Genetics Announces Receipt of $10 Million

2019-03-14 13:01:36 | What Type Of Shareholder Owns Atossa Genetics Inc.’s NASDAQ:ATOS?

2019-03-14 12:53:31 | Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing

2019-03-14 08:30:00 | Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient